伊那鲁单抗INN:ianalumab;开发代号:VAY736),或译伊利尤单抗,是一种单克隆抗体,正在被研究用于治疗自身免疫性肝炎多发性硬化症寻常型天疱疮英语Pemphigus vulgaris类风湿性关节炎干燥综合征系统性红斑狼疮[1][2][3]

伊那鲁单抗
单克隆抗体
种类?
目標B细胞激活因子英语B-cell activating factor
臨床資料
其他名稱VAY736、伊利尤单抗
ATC碼
  • 未分配
识别信息
CAS号1929549-92-7
UNII
KEGG

该药物由诺华公司开发。2021年,伊那鲁单抗正在进行II/III期试验。[4][5]2023年6月伊那鲁单抗参与了22项临床试验,其中3项已完成,14项正在进行,1项计划中,4项终止。[6]

参考资料

编辑
  1. ^ Ianalumab - MorphoSys/Novartis. AdisInsight. Springer Nature Switzerland AG. [2024-05-25]. (原始内容存档于2021-08-10). 
  2. ^ van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. Best Practice & Research. Clinical Rheumatology. February 2020, 34 (1): 101485. PMID 32067925. doi:10.1016/j.berh.2020.101485 . 
  3. ^ Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Current Opinion in Rheumatology. November 2020, 32 (6): 609–616. PMID 33002950. S2CID 222150641. doi:10.1097/BOR.0000000000000754. 
  4. ^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
  5. ^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
  6. ^ Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab. Pharmaceutical Technology. 30 June 2023 [2024-05-25]. (原始内容存档于2023-09-23).